-- Lead Program, BPT567, will be the first PD1-IL18 immunoconjugate to enter the clinic; Phase 1/2a study in solid tumors expected to begin in 2H 2024 – -- Financing led by Johnson & Johnson with...
Bright Peak Therapeutics has raised $90m in a Series C financing round as the biotech looks to make a name for itself in the immunoconjugate space.
SAN DIEGO and BASEL, Switzerland, April 09, 2024 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a biotechnology company developing multifunctional immunotherapies for cancer and autoimmune disease,...
Bright Peak Presents New Data at AACR: BPT567Â A First-in-Class Multifunctional PD1-IL18 Immunocytokine
SAN DIEGO and BASEL, Switzerland, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a privately held biotechnology company developing next-generation, multifunctional precision immunotherapies for cancer and autoimmune disease, today announced the presentation of multiple new cancer immunotherapy agents at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held on November 9-12, 2022, in Boston, MA.
SAN DIEGO and BASEL, Switzerland, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a privately held biotechnology company developing next-generation multifunctional precision immunotherapies, today announced the presentation of two posters showcasing the potential of its unique chemical protein engineering platform at the 10th International Conference on Autoimmunity: Mechanisms and Novel Treatments taking place October 20-25, 2022, in Chania, Crete.
SAN DIEGO and BASEL, Switzerland, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a biotechnology company developing next-generation precision immunotherapies to treat cancer and autoimmune disease, today announced the appointment of Jon Wigginton, M.D., as its President of Research and Development.
Bright Peak Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting
SAN DIEGO and BASEL, Switzerland, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and...